secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001564590-22-013022
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma's rNAPc2 fails to meet primary endpoint in Phase 2b COVID-19 trial
--------------------------------------------------------------------------------

- Pooled rNAPc2 reduced D-dimer 16.8% vs heparin 11.2% (P=0.47), missing statistical significance.
- Per-protocol analysis: rNAPc2 reduced D-dimer 28.7% vs heparin increase 1.1% (P=0.33).
- In WHO Severe patients, heparin D-dimer increased 29.0% (P=0.022); rNAPc2 changed 25.9% (P=0.16).
- Thrombotic events: 9 in heparin group vs 6 in rNAPc2; hazard ratio for recovery 0.88, neither significant.
- Company will not pursue direct superiority trial vs heparin for COVID-19; evaluating partnering and strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022013022/0001564590-22-013022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022013022/abio-8k_20220331.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-013022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer